NCT01088724View on ClinicalTrials.gov

Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)

PHASE4CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Post-transplant Lymphoproliferative Disease (PTLD)Non Burkitt
Interventions
DRUG

fludarabine, cyclophosphamide, doxorubicin, rituximab

Fludarabine i.v.(30 mg/sqm/day,day 1,2,3); Cyclophosphamide i.v.(750 mg/sqm, day 1); Doxorubicin i.v.(30 mg/sqm, day 1); Rituximab i.v. (375 mg/sqm, day 4).

Trial Locations (1)

24121

Ospedali Riuniti di Bergamo, Bergamo

All Listed Sponsors
lead

A.O. Ospedale Papa Giovanni XXIII

OTHER

NCT01088724 - Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD) | Biotech Hunter | Biotech Hunter